Lupin Limited — Others, 16-04-2025: Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

Lupin Limited has announced a board meeting regarding a patent dispute with Astellas Pharma over its generic product, Mirabegron. The U.S. District Court for Delaware ruled in favor of Astellas regarding the validity of its U.S. Patent No. 10,842,780. However, the trial addressing potential infringement by Lupin and damages is scheduled for 2026. Currently, the company anticipates no material financial implications from this ruling and maintains confidence in its legal position. Investors may find a positive outlook given the company's strong case and potential opportunities should the situation shift favorably.